Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EKSO

EKSO - Ekso Bionics Holdings Inc Stock Price, Fair Value and News

$8.55+0.29 (+3.51%)
Market Closed

24/100

EKSO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

24/100

EKSO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$6.97

Target 3M

$8

Target 6M

$7.4

EKSO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EKSO Price Action

Last 7 days

8.9%

Last 30 days

56.6%

Last 90 days

67.7%

Trailing 12 Months

-11.0%

EKSO RSI Chart

EKSO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EKSO Valuation

Market Cap

22.4M

Price/Earnings (Trailing)

-2.15

Price/Sales (Trailing)

1.52

Price/Free Cashflow

-2.5

EKSO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$6.97

Target 3M

$8

Target 6M

$7.4

EKSO Fundamentals

EKSO Revenue

Revenue (TTM)

14.7M

Rev. Growth (Yr)

2.37%

Rev. Growth (Qtr)

105.49%

EKSO Earnings

Earnings (TTM)

-10.4M

Earnings Growth (Yr)

31.42%

Earnings Growth (Qtr)

47.55%

EKSO Profitability

Return on Equity

-107.8%

Return on Assets

-48.17%

Free Cashflow Yield

-40.06%

EKSO Investor Care

Shares Dilution (1Y)

78.87%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202517.5M14.7M14.7M0
202417.9M18.2M17.7M17.9M
202314.4M15.8M17.1M18.3M
202211.9M13.0M13.3M12.8M
20218.2M8.1M8.3M11.2M
202011.8M10.8M10.3M7.8M
201912.4M12.7M13.5M13.9M
20188.4M9.5M10.5M11.3M
20177.2M7.5M7.5M7.4M
201615.5M14.9M13.6M14.2M
20156.0M6.9M8.2M8.7M
20143.7M3.9M4.6M5.3M
20133.4M4.4M5.2M3.3M
20120002.7M
Get all data in R, Python etc through our Historical Stock Data APIs

About Ekso Bionics Holdings Inc

EKSO
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therap, an adjustable and lower-limb powered exoskeleton; and Ekso Indego Personal, a powered lower limb orthosis. It has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in San Rafael, California.
 CEO
 WEBSITEeksobionics.com
 SECTORHealthcare
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES72

Ekso Bionics Holdings Inc Frequently Asked Questions

EKSO is the stock ticker symbol of Ekso Bionics Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Ekso Bionics Holdings Inc is 22.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check EKSO's fair value in chart for subscribers.

The fair value guage provides a quick view whether EKSO is over valued or under valued. Whether Ekso Bionics Holdings Inc is cheap or expensive depends on the assumptions which impact Ekso Bionics Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EKSO.

As of Wed Jan 28 2026, EKSO's PE ratio (Price to Earnings) is -2.15 and Price to Sales (PS) ratio is 1.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EKSO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Ekso Bionics Holdings Inc has provided -0.399 (multiply by 100 for percentage) rate of return.